Navigation Links
immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
Date:9/21/2010

cal study in approx. 90 patients with advanced colorectal cancer. The Company's third clinical project, IMA950 is in preparation for two Phase I studies in patients with glioblastoma in collaboration with Cancer Research UK and with the National Cancer Institute in the US. Furthermore, the Company will seek to move IMA941 for treatment of gastric cancer patients in East Asia into the clinic and will continue to expand and further improve its XPRESIDENT(TM) antigen discovery platform.

immatics' pipeline of advanced therapeutic vaccines has been developed using the unique XPRESIDENT(TM) technology. This platform has the ability to identify specific tumor associated peptides (TUMAPS) related to any cancer type in a fast and reliable manner. This allows the company to generate better cancer vaccines rapidly, to patent them and to move new vaccine candidates into the clinic in less than 24 months. Additionally, immatics' XPRESIDENT(TM) technology can be used to identify disease associated peptides in areas beyond cancer.

Paul Higham, CEO of immatics said: "Attracting such financial backing from leading European biotech investors demonstrates a strong belief in our company and development programs. With this financing now in place, we can fully focus on the further clinical development of our three leading cancer vaccine programs. Importantly, we are now able to move our lead program, IMA901 in renal cell carcinoma into a Phase III pivotal study by the end of this year, a key step in bringing promising novel therapeutic vaccines to cancer patients. This Series C financing will also allow us to invest in developing our other vaccine candidates and to explore further the potential of our underlying XPRESIDENT(TM) technology platform."

Dr. Matthias Kromayer from MIG AG commented: "It is increasingly clear that therapeutic vaccines have the potential to revolutionize the treatment of cancer. We were very impressed by the Phase II results immatics gener
'/>"/>

SOURCE immatics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
2. StatRad Raises the Bar With Fully Integrated Teleradiology Solution
3. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
4. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
5. Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
6. SynapDx Corporation Raises $9 Million in Series A Funding
7. NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
8. Curexo Technology Corporation Raises $13.2 Million
9. Cardinal Health Raises Quarterly Dividend By 11 Percent
10. IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment
11. Intercept Pharmaceuticals Raises $25 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 The ... http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & Johnson’s ... bellwether trial, which is expected to get underway next ... in the U.S. District Court, Southern District of West ... be held on August 7, 2014 at 3:00 p.m. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... by Wright & Schulte LLC to provide consumers with ... can sometimes accompany use of the blood-thinning medication, as ... lawsuits pending in courts around the country. The ... anyone who may have suffered from life-threatening internal bleeding ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
... stigma is powerful, pervasive and destructive," said Marlene Schwartz, a ... reactions to two prom photos.// , One showed a ... woman. The other was the same photo altered to show ... ,The volunteers took a quick look at one or ...
... may be much more likely to have asthma and a nighttime ... from Australia.// ,Doctors often use night cough as a guide ... the August issue of Chest, suggest it may be appropriate to ... ,"Night cough is often taken as a sign of the onset ...
... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
... New research shows the same drugs you take to ... ,Researchers from the University of Pittsburgh followed more than ... than seven years. Results of the study show more ... cholesterol-lowering drugs developed breast cancer, while 2.1 percent of ...
... proved exercise reduces the risk of breast cancer, and now ... may lower a woman’s risk of developing breast carcinoma in ... into invasive breast cancer if left untreated. ,Researchers from ... 35 and 64 years old. More than 550 participants had ...
... Lung cancer is by far the biggest cancer killer around the ... survey researchers found that 38 percent of 626 patients they ... 61 percent of the black and 29 percent of the white ... air would cause it to spread., Most of the patients were ...
Cached Medicine News:Health News:False beliefs could cost cancer patients their lives 2
... Discovery 90SE Ultracentrifuge offers ... discover more. All the ... top-of-the-line performance, powerful functionality, ... use, all built into ...
... centrifuge continues to raise the standard for ... 1,048,000 x g performance and our new ... sample sizes from 0.2 ml to 8.3 ... direct drive, very quiet operation, rotor imbalance ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
Medicine Products: